[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483279":3},{"organization":4,"outcomesModule":7,"designInfo":7,"detailedDescription":8,"studyPopulation":7,"armGroups":7,"interventions":9,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":105,"collaborators":7,"id":107,"slug":7,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":7,"eligibilityCriteria":112,"healthyVolunteers":108,"sex":113,"minAge":114,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":115,"phases":7,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":34,"whyStopped":7,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Agenus Inc.","INDUSTRY",null,"This study will not exceed 100 participants. Participants will be reevaluated annually to assess the treatment benefit of zalifrelimab and\u002For balstilimab and thereby, continued eligibility for treatment. Under this program, treatment will be continued with balstilimab, as either monotherapy or as used in combination therapy with zalifrelimab, for participants that have previously received one or both of these investigational medicinal products in a clinical study.",[10,16],{"type":11,"name":12,"description":13,"armGroupLabels":7,"otherNames":14},"DRUG","Balstilimab","An anti-programmed death 1 (PD-1) monoclonal antibody.",[15],"AGEN2034",{"type":11,"name":17,"description":18,"armGroupLabels":7,"otherNames":19},"Zalifrelimab","An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.",[20],"AGEN1884",[22],{"name":23,"affiliation":5,"role":24},"Medical Director","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":7,"email":30},"Agenus, Inc.","CONTACT","781-674-4265","clinicaltrialinfo@Agenusbio.com",[32,46,56,66,75,85,95],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":7},"University of Alabama at Birmingham","AVAILABLE","Birmingham","Alabama","35249","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-86.80249,33.52066,{"lat":44,"lon":43},{"facility":47,"status":34,"city":48,"state":49,"zip":50,"country":38,"countryCode":39,"cosmosGeoPoint":51,"geoPoint":55,"contacts":7},"Arizona Oncology Associates","Tucson","Arizona","85711",{"type":41,"coordinates":52},[53,54],-110.92648,32.22174,{"lat":54,"lon":53},{"facility":57,"status":34,"city":58,"state":59,"zip":60,"country":38,"countryCode":39,"cosmosGeoPoint":61,"geoPoint":65,"contacts":7},"Hoag Gynecologic Oncology","Newport Beach","California","92663",{"type":41,"coordinates":62},[63,64],-117.92895,33.61891,{"lat":64,"lon":63},{"facility":67,"status":34,"city":68,"state":59,"zip":69,"country":38,"countryCode":39,"cosmosGeoPoint":70,"geoPoint":74,"contacts":7},"University of California, San Francisco Medical Center","San Francisco","94158",{"type":41,"coordinates":71},[72,73],-122.41942,37.77493,{"lat":73,"lon":72},{"facility":76,"status":34,"city":77,"state":78,"zip":79,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":84,"contacts":7},"The Ohio State University Wexner Medical Center","Columbus","Ohio","43212",{"type":41,"coordinates":81},[82,83],-82.99879,39.96118,{"lat":83,"lon":82},{"facility":86,"status":34,"city":87,"state":88,"zip":89,"country":38,"countryCode":39,"cosmosGeoPoint":90,"geoPoint":94,"contacts":7},"Women & Infants Hospital of Rhode Island","Providence","Rhode Island","02905",{"type":41,"coordinates":91},[92,93],-71.41283,41.82399,{"lat":93,"lon":92},{"facility":96,"status":34,"city":97,"state":98,"zip":99,"country":38,"countryCode":39,"cosmosGeoPoint":100,"geoPoint":104,"contacts":7},"Texas Oncology","Flower Mound","Texas","75028",{"type":41,"coordinates":101},[102,103],-97.09696,33.01457,{"lat":103,"lon":102},{"type":106,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100483279",false,"NCT05572970","Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)","Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)","Inclusion Criteria:\n\n* Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","EXPANDED_ACCESS","This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and\u002For wish to continue treatment, and who are eligible for treatment under this expanded access study.",[118],"Cancer",[12,15,17,20,120],"Monotherapy","2026-05-05",{"date":123,"type":124},"2026-05-06","ACTUAL",{"name":5,"class":6},7]